Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Galmed Pharmaceuticals Ltd. (GLMD) had Return on Tangible Equity of -12.16% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-2.50M |
|
-- |
|
-- |
|
$2.11M |
|
$-2.11M |
|
$-0.39M |
|
$-2.50M |
|
$-1.97M |
|
$-2.50M |
|
$-2.50M |
|
$-2.50M |
|
$-1.97M |
|
$-2.11M |
|
$-2.13M |
|
3.95M |
|
3.95M |
|
$-0.63 |
|
$-0.63 |
|
| Balance Sheet Financials | |
$21.08M |
|
-- |
|
$1.86M |
|
$22.94M |
|
$2.42M |
|
-- |
|
-- |
|
$2.42M |
|
$20.52M |
|
$20.52M |
|
$20.52M |
|
5.30M |
|
| Cash Flow Statement Financials | |
$-2.44M |
|
$-4.80M |
|
$7.55M |
|
$4.77M |
|
$5.09M |
|
$0.31M |
|
$0.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.44M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.16% |
|
|
Return on Tangible Equity |
-12.16% |
-10.87% |
|
-12.16% |
|
$3.87 |
|
$-0.62 |
|
$-0.62 |
|